𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women

✍ Scribed by Catherine Schairer; Deirdre Hill; Susan R. Sturgeon; Thomas Fears; Michael Pollak; Carolyn Mies; Regina G. Ziegler; Robert N. Hoover; Mark E. Sherman

Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
88 KB
Volume
108
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Experimental evidence suggests that insulin and insulin‐related growth factors may play a role in breast pathology through their mitogenic and anti‐apoptotic effects on breast cells. Our objective was to assess the relationship between serum concentrations of insulin‐like growth factor‐I (IGF‐I), its major binding protein (IGFBP‐3), the ratio IGF‐I:IGFBP‐3, c‐peptide (a marker of insulin secretion) and the ratio c‐peptide:fructosamine (a marker of insulin resistance) and the risk of epithelial hyperplasia (an established breast cancer risk factor) and localized breast cancer among postmenopausal women. Study subjects were patients who provided serum before breast biopsy or mastectomy in 3 hospitals in Grand Rapids, MI between 1977 and 1987. Two case groups, 186 subjects with epithelial hyperplasia of the breast and 185 subjects with localized breast cancer, were compared to 159 subjects with nonproliferative breast changes that have not been associated with increased breast cancer risk. Serum concentrations of IGF‐I, IGFBP‐3 and the ratio IGF‐I:IGFBP‐3 were not related to risk of either hyperplasia or breast cancer. For women in the highest quartile of c‐peptide or of c‐peptide:fructosamine compared to those in the lowest quartile, the odds ratios (ORs) for hyperplasia were 3.0 (95% confidence interval [CI] 1.4–6.5) and 3.3 (95% CI 1.5–7.3), respectively (p trend = 0.02 and 0.02, respectively). The corresponding ORs for breast cancer were 1.5 (95% CI 0.7–3.0) and 1.6 (95% CI 0.8–3.2), respectively (p trend = 0.35 and 0.25, respectively). Our results suggest that insulin and insulin resistance may play a role in breast pathology in postmenopausal women. © 2003 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Prediagnostic levels of C-peptide, IGF-I
Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer
✍ Annekatrin Lukanova; Anne Zeleniuch-Jacquotte; Eva Lundin; Andrea Micheli; Alan 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 122 KB 👁 1 views

## Abstract Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF‐I and decreased levels of IGF‐binding proteins have been shown to be as

Serum concentrations of estrogens, sex h
Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women
✍ Laila Adly; Deirdre Hill; Mark E. Sherman; Susan R. Sturgeon; Thomas Fears; Caro 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 91 KB 👁 1 views

## Abstract We assessed the relationship between serum concentrations of estrogens, androgens, and sex hormone‐binding globulin and risk of breast cancer among postmenopausal women. Study participants provided serum prior to breast biopsy or mastectomy in 3 hospitals in Grand Rapids, Michigan betwe

Serum C-peptide, IGFBP-1 and IGFBP-2 and
Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition
✍ Mazda Jenab; Elio Riboli; Rebecca J. Cleveland; Teresa Norat; Sabina Rinaldi; Al 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 114 KB 👁 1 views

## Abstract Western style diets and lifestyles are associated with increasing rates of obesity, diabetes and insulin resistance. Higher circulating insulin levels may modulate cell proliferation and apoptosis either directly or indirectly by increasing the bioactivity of IGF‐I and decreasing the bi

Effect of fenretinide on plasma IGF-I an
Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients
✍ Rosalba Torrisi; Stefano Parodi; Vincenzo Fontana; Floriana Pensa; Claudia Casel 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 70 KB 👁 2 views

Growing evidence substantiates the role of the insulin-like growth factor I (IGF-I) system in breast tumorigenesis. Retinoids have been shown to affect the IGF system in several experimental models. We extended our previous data on plasma IGF-I modulation by the synthetic retinoid fenretinide (4-HPR

Serum levels of C-peptide, IGFBP-1 and I
Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; Results from the European prospective investigation into cancer and nutrition
✍ Anne E. Cust; Naomi E. Allen; Sabina Rinaldi; Laure Dossus; Christine Friedenrei 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 203 KB 👁 1 views

## Abstract We conducted a case‐control study nested within the European Prospective Investigation into Cancer and Nutrition, to examine the associations between prediagnostic serum concentrations of C‐peptide, insulin‐like growth factor binding protein (IGFBP)‐1 and IGFBP‐2, and endometrial cancer

Genetic variation and circulating levels
Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease
✍ Xuefen Su; Graham A. Colditz; Walter C. Willett; Laura C. Collins; Stuart J. Sch 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 157 KB 👁 1 views

## Abstract Insulin‐like growth factor‐I (IGF‐I) and its major binding protein IGFBP‐3 have been implicated in breast carcinogenesis. We examined the associations between genetic variants and circulating levels of IGF‐I and IGFBP‐3 with proliferative benign breast disease (BBD), a marker of increas